![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV)
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Lok DF, Hezode C, Lawitz EJ, ok AS, Gardiner F, He ode awit J, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang S-P, Wind-Rotolo M, McPhee F, Grasela DM, and Pasquinelli C
![AASLD1.gif](../images/111312/111312-15/AASLD1.gif)
![AASLD2.gif](../images/111312/111312-15/AASLD2.gif)
![AASLD3.gif](../images/111312/111312-15/AASLD3.gif)
![AASLD4.gif](../images/111312/111312-15/AASLD4.gif)
![AASLD5.gif](../images/111312/111312-15/AASLD5.gif)
![AASLD6.gif](../images/111312/111312-15/AASLD6.gif)
![AASLD7.gif](../images/111312/111312-15/AASLD7.gif)
![AASLD8.gif](../images/111312/111312-15/AASLD8.gif)
![AASLD9.gif](../images/111312/111312-15/AASLD9.gif)
![AASLD10.gif](../images/111312/111312-15/AASLD10.gif)
![AASLD11.gif](../images/111312/111312-15/AASLD11.gif)
![AASLD12.gif](../images/111312/111312-15/AASLD12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|